Changes in RDW according to prognostic predictors in newly diagnosed multiple myeloma

[1]  A. Hinke,et al.  SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of ‘biomarker-defined early multiple myeloma’—a systematic review with meta-analysis , 2023, EClinicalMedicine.

[2]  G. Caimi,et al.  The unpredictable erythrocyte deformability alteration in some hematological disorders: How the classification of primary hyperviscosity syndromes could change. , 2023, Clinical hemorheology and microcirculation.

[3]  G. Caimi,et al.  Erythrocyte deformability profile evaluated by laser diffractometry in patients with multiple myeloma: Re-examination of our cases. , 2022, Microvascular research.

[4]  J. Suh,et al.  Red Blood Cell Deformability and Distribution Width in Patients with Hematologic Neoplasms. , 2022, Clinical laboratory.

[5]  Jiayue Liu,et al.  Is RDW a clinically relevant prognostic factor for newly diagnosed multiple myeloma? A systematic review and meta-analysis , 2022, BMC cancer.

[6]  Tracy Holloway King,et al.  Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR) , 2022, British journal of haematology.

[7]  A. Kraśniak,et al.  The Key Role of Hepcidin-25 in Anemia in Multiple Myeloma Patients with Renal Impairment , 2022, Medicina.

[8]  R. Fonseca,et al.  A simple additive staging system for newly diagnosed multiple myeloma , 2022, Blood cancer journal.

[9]  F. Zhou,et al.  Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents , 2021, Hematological oncology.

[10]  D. Niederwieser,et al.  The diagnostic red blood cell distribution width as a prognostic factor in acute myeloid leukemia , 2021, Blood advances.

[11]  Bing Li,et al.  RBC distribution width predicts thrombosis risk in polycythemia vera , 2021, Leukemia.

[12]  G. Caimi,et al.  Reflections on the unexpected laboratory finding of hemorheological alterations observed in some haematological disorders. , 2021, Microvascular research.

[13]  Ming-feng Jia,et al.  Higher red blood cell distribution width at diagnose is a simple negative prognostic factor in chronic phase-chronic myeloid leukemia patients treated with tyrosine kinase inhibitors , 2021, Medicine.

[14]  ZhanZe Chen,et al.  Higher Red Blood Cell Distribution Width is a Poor Prognostic Factor for Patients with Chronic Myeloid Leukemia , 2021, Cancer management and research.

[15]  A. Turgutkaya,et al.  The relationship between red cell distribution width and prognostic scores in myelodysplastic syndrome , 2021, Hematology, transfusion and cell therapy.

[16]  L. Costa,et al.  Revisiting the impact of immunoglobulin isotypes in multiple myeloma , 2020, Annals of Hematology.

[17]  H. Holik,et al.  Higher red blood cell distribution width might differentiate primary from secondary polycythemia: A pilot study , 2020, International journal of laboratory hematology.

[18]  Xiaojun Huang,et al.  Serum Lactate Dehydrogenase Can Be Used as a Factor for Re-Evaluating First-Relapsed Multiple Myeloma , 2020, Acta Haematologica.

[19]  D. Dingli,et al.  Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. , 2020, Clinical lymphoma, myeloma & leukemia.

[20]  V. Jimenez-Zepeda,et al.  The Prognostic Role of Lactate Dehydrogenase at First Relapse of Multiple Myeloma , 2020, Acta Haematologica.

[21]  Filip Krečak,et al.  High red blood cell distribution width might predict thrombosis in essential thrombocythemia and polycythemia vera. , 2020, Blood cells, molecules & diseases.

[22]  M. Nakashima,et al.  IgA plasma cell neoplasms are characterized by poorer long-term survival and increased genomic complexity compared to IgG neoplasms. , 2019, Annals of diagnostic pathology.

[23]  Bing Li,et al.  Prognostic impact of red blood cell distribution width in myelodysplastic syndromes , 2019, British journal of haematology.

[24]  Azhar Hussain,et al.  Laboratory Features of Newly Diagnosed Multiple Myeloma Patients , 2019, Cureus.

[25]  S. Iida,et al.  JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM) , 2019, International Journal of Hematology.

[26]  Jian-yong Li,et al.  [Prognostic Value of Red Blood Cell Distribution Width in Senile Potients with Non-trans planted Multiple Myeloma]. , 2019, Zhongguo shi yan xue ye xue za zhi.

[27]  Peipei Xu,et al.  Pre-treatment red blood cell distribution width provides prognostic information in multiple myeloma. , 2018, Clinica chimica acta; international journal of clinical chemistry.

[28]  F. Jin,et al.  IgA Type Multiple Myeloma, Clinical Features, and Prognosis , 2018, Chinese medical journal.

[29]  Yu Hu,et al.  Prognostic role of RDW in hematological malignancies: a systematic review and meta-analysis , 2018, Cancer Cell International.

[30]  T. Nakamaki,et al.  Association of red cell distribution width with clinical outcomes in myelodysplastic syndrome. , 2018, Leukemia research.

[31]  H. Goldschmidt,et al.  Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels , 2018, Haematologica.

[32]  G. Caimi,et al.  Erythrocyte deformability and hemorheological profile in multiple myeloma. , 2017, Clinical hemorheology and microcirculation.

[33]  A. Allegra,et al.  Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma , 2017, Mediators of inflammation.

[34]  Jun Xia,et al.  Evaluation of pretreatment red cell distribution width in patients with multiple myeloma. , 2017, Cancer biomarkers : section A of Disease markers.

[35]  Chenyang Lu,et al.  Prognostic Value of Elevated Red Blood Cell Distribution Width in Chinese Patients with Multiple Myeloma , 2017, Annals of clinical and laboratory science.

[36]  Jian-yong Li,et al.  High serum lactate dehydrogenase predicts an unfavorable outcome in Chinese elderly patients with multiple myeloma , 2017, Oncotarget.

[37]  K. Stamatopoulos,et al.  Distinct Immunogenetic Signatures in IgA Versus IgG Multiple Myeloma , 2016 .

[38]  O. Jakšić,et al.  The Degree of Anisocytosis Predicts Survival in Patients with Primary Myelofibrosis , 2016, Acta Haematologica.

[39]  M. Nikiforov,et al.  Oxidative stress and proteasome inhibitors in multiple myeloma. , 2016, Pharmacological research.

[40]  C. Teng,et al.  Early mortality in multiple myeloma: Experiences from a single institution , 2016, Hematology.

[41]  E. Solá,et al.  Association of erythrocyte deformability with red blood cell distribution width in metabolic diseases and thalassemia trait. , 2016, Clinical hemorheology and microcirculation.

[42]  M. Takei,et al.  Higher Red Blood Cell Distribution Width Is an Adverse Prognostic Factor in Chronic-phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors. , 2015, Anticancer research.

[43]  J. Higgins,et al.  Modulation of red blood cell population dynamics is a fundamental homeostatic response to disease , 2015, American journal of hematology.

[44]  H. Goldschmidt,et al.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. , 2014, The Lancet. Oncology.

[45]  D. Grandér,et al.  IL-6 activated JAK/STAT3 pathway and sensitivity to Hsp90 inhibitors in multiple myeloma. , 2014, Current medicinal chemistry.

[46]  Hong Liu,et al.  Hepcidin and GDF15 in anemia of multiple myeloma , 2014, International Journal of Hematology.

[47]  Hyoeun Shim,et al.  Elevated Red Blood Cell Distribution Width as a Simple Prognostic Factor in Patients with Symptomatic Multiple Myeloma , 2014, BioMed research international.

[48]  M. Dimopoulos,et al.  High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents , 2010, European journal of haematology.

[49]  Sang-We Kim,et al.  Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma , 2010, Annals of Hematology.

[50]  A. Órfão,et al.  Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells , 2010, British journal of haematology.

[51]  G. Lippi,et al.  Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients. , 2009, Archives of pathology & laboratory medicine.

[52]  A. Bleyer,et al.  Malignant melanoma in the first three decades of life: A report from the U.S. Surveillance, Epidemiology and End Results (SEER) Program , 2004 .

[53]  V. Lauta,et al.  A review of the cytokine network in multiple myeloma , 2003, Cancer.

[54]  M. C. Magalhães,et al.  Hypoalbuminemia in patients with multiple myeloma. , 1990, Archives of internal medicine.

[55]  H. Khalkhali,et al.  Serum levels of bone sialoprotein, osteopontin, and β2-microglobulin in stage I of multiple myeloma. , 2020, Journal of cancer research and therapeutics.

[56]  G. Caimi,et al.  Red blood cell deformability in multiple myeloma1. , 2018, Clinical hemorheology and microcirculation.

[57]  A. Vayá,et al.  Red blood cell distribution width and erythrocyte deformability in patients with acute myocardial infarction. , 2015, Clinical hemorheology and microcirculation.

[58]  T. Grodzicki,et al.  Association of red blood cell distribution width, inflammation markers and morphological as well as rheological erythrocyte parameters with target organ damage in hypertension. , 2014, Clinical hemorheology and microcirculation.

[59]  K. Patel,et al.  Association of the red cell distribution width with red blood cell deformability. , 2013, Advances in experimental medicine and biology.

[60]  M. Trivett,et al.  Bone marrow plasma cell microaggregates detected by immunohistology predict earlier relapse in patients with minimal disease after high-dose therapy for myeloma. , 2005, Haematologica.

[61]  E. Keller,et al.  Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. , 2000, Annual review of medicine.